Diagnostic Yield of Bronchoalveolar Lavage Is Low in Allogeneic Hematopoietic Stem Cell Recipients Receiving Immunosuppressive Therapy or with Acute Graft-versus-Host Disease: The St. Jude Experience, 1990-2002  by Kasow, Kimberly A. et al.
D
i
R
G
1
Biology of Blood and Marrow Transplantation 13:831-837 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1307-0001$32.00/0
doi:10.1016/j.bbmt.2007.03.008iagnostic Yield of Bronchoalveolar Lavage Is Low
n Allogeneic Hematopoietic Stem Cell Recipients
eceiving Immunosuppressive Therapy or with Acute
raft-versus-Host Disease: The St. Jude Experience,
990-2002
Kimberly A. Kasow,1 Erin King,2 Richard Rochester,1 Xin Tong,3 Deo Kumar Srivastava,3
Edwin M. Horwitz,1 Wing Leung,1 Paul Woodard,1 Rupert Handgretinger,1 Gregory A. Hale1
1Division of Bone Marrow Transplantation, St. Jude Children’s Research Hospital, Memphis, Tennessee; 2Chicago
College of Osteopathic Medicine, Downers Grove, Illinois; 3Department of Biostatistics, St. Jude Children’s
Research Hospital, Memphis, Tennessee
Correspondence and reprint requests: Kimberly A. Kasow, DO, Division of Bone Marrow Transplantation, St. Jude
Children’s Research Hospital, 332 North Lauderdale, MS 260, Memphis, TN 38105 (e-mail: kimberly.kasow@
stjude.org).
Received September 12, 2006; accepted March 16, 2007
ABSTRACT
Management of pulmonary complications after hematopoietic stem cell transplantation (HSCT) often includes
bronchoalveolar lavage (BAL), but the diagnostic yield of BAL remains unclear in pediatric HSCT patients. We
reviewed the records of 78 allogeneic and 11 autologous transplant recipients who underwent BAL after HSCT
at St. Jude Children’s Research Hospital (1990-2002). We analyzed donor and recipient information, clinical
variables, adverse events during bronchoscopy, outcome, and medical management at the time of the proce-
dure to determine the diagnostic yield of BAL and factors that affect its success. Seventy-eight allogeneic and
11 autologous transplant recipients underwent BAL at a median of 68 days (range, 6-528 days) and 23 days
(range, 6-705 days) after HSCT, respectively. The median age at the time of BAL was 12.2 years (0.8-23.5
years) in allogeneic patients and 16.9 years (4.8-26.2 years) in autologous patients. The most common
indications for BAL in both populations were fever, hypoxia, and abnormality on chest auscultation. BAL
identified an etiology in 53 allogeneic (67.9%) and 7 autologous (63.6%) patients (BAL positive); only 1 etiology
was identified in 30 of the 53 allogeneic patients (56.6%). The most common finding was bacterial infection in
both allogeneic (59.0%) and autologous (71.4%) patients. Of 39 allogeneic patients who had concurrent
extrapulmonary infection, 30 (76.9%) had a positive BAL. Seven (9.0%) allogeneic patients experienced hypoxia
(generally transient) during bronchoscopy. Approximately 68% of those with a positive BAL were receiving
immunosuppressive therapy, whereas 96% of patients with a negative BAL were receiving immunosuppressive
therapy (P  .008). Further, 26.4% of the BAL-positive cohort had grade II-IV acute graft-versus-host disease
(aGVHD), whereas 60% of the BAL-negative group had grade II-IV aGVHD (P .004). In our experience, the
safety and diagnostic yield of BAL in this set of patients is relatively high, but the likelihood of informative
findings is reduced among allogeneic recipients with grade II-IV aGVHD and those receiving immunosup-
pressive therapy.
© 2007 American Society for Blood and Marrow Transplantation
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Respiratory complications are common (occurring
n 40%-60% of patients) after hematopoietic stem cell
ransplantation (HSCT) [1]. As the differential diag-
osis is broad and speciﬁc therapies may incur risk,
ptimal treatment depends on an accurate diagnosis.
mmunocompromised patients are vulnerable to mul-
iple causes of respiratory deterioration, including the
rimary disease, previous therapy, infection, and
raft-versus-host disease (GVHD) [2].
Bronchoalveolar lavage (BAL) is a diagnostic tool
sed to obtain specimens in children with respiratory
ecompensation who have undergone HSCT, but its
ield in these patients has been variable and the pro-
edure carries certain risks. Furthermore, we are un-
ware whether certain groups of patients may have a
reater beneﬁt from undergoing a BAL. Therefore,
e conducted a retrospective study to determine the
ate of complications with BAL in children who have
ndergone HSCT, the diagnostic value of BAL, and
atient characteristics that predict the likelihood that
he procedure will be of beneﬁt.
ATERIALS AND METHODS
atients
After obtaining approval from the St. Jude Chil-
ren’s Research Hospital Institutional review board
IRB), we retrospectively reviewed the charts of 89
atients who had undergone HSCT at St. Jude be-
ween 1990 and 2002, and a BAL as identiﬁed by the
ransplant and Gene Therapy database. Information
athered from the medical records and the transplant
atabase included type of HSCT (allogeneic or autol-
gous), primary diagnosis, disease status at the time of
SCT, age at the time of BAL, and previous alloge-
eic or autologous HSCT. Recipients received my-
loablative conditioning before allogeneic HSCT and
igh-dose chemotherapy before autologous HSCT.
ll transplant protocols were IRB-approved, and
igned informed consent for protocol or best clinical
anagement plan was obtained from parents or the
atients prior to the initiation of therapy. Patients
eceived preparative regimens that have been previ-
usly published [3-6]. Survivors were followed at St.
ude until either 10 years posttransplantation or 18
ears of age, which ever occurred last.
AL Procedure
Bronchoalveolar lavage was performed by a pul-
onologist, using a ﬁberoptic bronchoscope of the
ppropriate size. Transbronchial biopsy was per-
ormed at the time of BAL at the discretion of the
ulmonologist. Specimens were sent for pathology
eview and microbiological evaluation that included tram stain, silver stain, and bacterial, viral, and fungal
ulture. A diagnosis of inﬂammation was made by the
athologist if inﬂammatory cells were present, regard-
ess of whether an infectious etiology was identiﬁed.
ariables Analyzed
For recipients of allogeneic HSCT, we analyzed
onor type (matched sibling, unrelated, or partially
ismatched family member), recipient and donor cy-
omegalovirus (CMV) serologic status, graft manipu-
ation (T cell depletion), the stem cell source (bone
arrow or mobilized peripheral blood stem cells), the
resence and extent of aGVHD and chronic graft-
ersus-host disease (cGVHD), and the use of immu-
osuppressive therapy (such as cyclosporine, methyl-
rednisolone) at the time of BAL. Adverse events
uring BAL and ﬁnal diagnosis were documented. We
lso reviewed the number of transbronchial biopsies
erformed at the time of BAL as well as the number of
pen-lung biopsies performed.
For all patients studied, we also noted the history
f pre-HSCT pulmonary complications; age at the
ime of HSCT and BAL; day post-HSCT when BAL
as performed; the frequency of respiratory symp-
oms that prompted the procedure; neutrophil en-
raftment status (ANC 500/L); concurrent infec-
ious illness (bacterial, viral, or fungal infection or
olonization); antimicrobial, antifungal, and antiviral
herapy at the time of BAL, including prophylactic
nd treatment agents; survival status; and cause of
eath. Chest radiographs and computed tomography
CT) imaging reports prior to BAL were reviewed.
e also noted whether patients were intubated before
AL and whether intubation was elective or urgent.
tatistical Analysis
If patients underwent multiple BAL procedures,
nly the ﬁrst was included in this analysis. BAL was
onsidered nondiagnostic (negative) if it provided no
tiologic information. If any etiology for the respira-
ory dysfunction was identiﬁed, the BAL was consid-
red diagnostic (positive). The differences in the dis-
ribution of categorical clinical and biological features
etween patients with positive and negative BAL were
xamined by using 2-tailed Fisher’s or chi-square ex-
ct tests. The differences between continuous vari-
bles were examined by using the Student’s t test. The
riterion for statistical signiﬁcance in all analyses was
P value .05. All statistical analyses were performed
ith SAS Release 9.1 software (Cary, NC).
ESULTS
atient Characteristics
Bronchoalveolar lavage was performed on 89 of
he 917 patients who had received HSCT during the
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Bronchoalveolar Lavage in Pediatric HSCT 833tudy period (401 autologous and 516 allogeneic).
eventy-eight (87.6%) were the recipients of alloge-
eic transplants and 11 (12.4%) received autologous
ransplants; 8 had undergone previous HSCTs. The
edian age at the time of HSCT was 12.8 years
range: 0.7-26.2 years). Seventy-nine of 87 patients
90.8%) who had diagnostic imaging studies had ab-
ormal ﬁndings; evidence that imaging was performed
rior to the procedure could not be found for 2 pa-
ients. The clinical characteristics of the patients and
ransplants are summarized in Table 1.
utologous Recipients
Eleven patients received autologous HSCT. The
edian age at the time of BAL was 16.9 years (range:
.8-26.2 years), and the median time between HSCT
nd BAL was 23 days (6-705 days). Only 1 patient had
BAL greater than 1 year from HSCT. Three pa-
ients had a history of previous pulmonary complica-
able 1. Disease- and Transplant-Related Factors of the 89 Patients
ho Underwent a BAL after HSCT
Primary Disease N  Patients
cute lymphoblastic leukemia 22
cute myelogenous leukemia 27
hronic myelogenous leukemia 13
Chronic phase 1 7
Chronic phase 2 1
Accelerated phase 4
Refractory phase 1
yelodysplastic syndrome 5
on-Hodgkin lymphoma 8
odgkin lymphoma 1
uvenile myelomonocytic leukemia 2
anconi anemia 1
evere aplastic anemia 3
amiliar erythrophagocytic
lymphohistiocytosis 1
iskott-Aldrich syndrome 2
edulloblastoma 2
lioblastoma 1
wing sarcoma 1
onor stem cell source
Bone marrow 82
Mobilized peripheral blood 7
llogeneic stem cell donor
Matched sibling 31
Unrelated donor 39
Partially mismatched family member 8
cell depletion of the graft
Yes 48
No 41
Allogeneic graft 30
Autologous graft 11
elapse risk classification (allogeneic HSCT)
Standard risk (CR1, CR2, chronic phase) 45
High risk (>CR2, refractory disease, MDS
< accelerated phase) 25
Nonmalignant disease (not classified) 8
R indicates complete remission; HSCT, hematopoietic stem cell
htransplantation; MDS, myelodysplastic syndrome.ions prior to HSCT. The most frequent symptoms
rior to BAL, as reported by frequency of symptoms,
ere hypoxia (31.6%), fever (21.1%), cough, and ab-
ormal auscultation (15.8% each). Radiographically,
ither by chest radiograph or chest CT, 8 patients had
diffuse pulmonary process and 2 had focal disease
resent prior to BAL. One patient had normal imag-
ng. Five of 11 patients were electively intubated and
were urgently intubated prior to the procedure.
nly 1 patient did not require intubation. Six of the
1 patients (54.5%) had achieved neutrophil engraft-
ent. Nine patients (81.8%) were receiving antibiot-
cs, 8 (72.7%) were receiving antifungal medications,
nd 5 (45.5%) were receiving antiviral medications.
AL was positive in 7 of 11 patients (63.6%). Of these
patients, 6 had 1 etiologic ﬁnding and 1 had 3
ositive ﬁndings. The most common positive diag-
oses were bacterial infection (38.5%), alveolar hem-
rrhage (23.1%), and inﬂammation as characterized
y the pathologist (7.7%). Four autologous patients
ad concurrent infections, with 3 having a positive
AL and 1 a negative BAL. Results of BAL did not
orrespond to previous pulmonary complications
rior to HSCT. Only 1 patient suffered a procedure
omplication, which was hypoxia. One patient had a
ransbronchial biopsy at the time of BAL that was
egative, and 1 patient proceeded to have an open
ung biopsy, which revealed pulmonary ﬁbrosis.
llogeneic Recipients
Time to BAL and Indications for BAL. The median
ge of the 78 allogeneic recipients at the time of BAL
as 12.2 years (range: 0.8-23.5 years) and a median of
8 days (range: 6-528 days) elapsed between HSCT
nd BAL. Only 1 allogeneic patient underwent BAL
1 year after HSCT. Twenty-six of the allogeneic
atients (33.3%) had a history of previous pulmonary
roblems prior to HSCT. Sixty-six (84.6%) patients
ad experienced neutrophil engraftment at the time of
he procedure. Most patients had 1 to 3 clinical signs
nd symptoms that prompted BAL, including the fol-
owing, reported as a percentage of frequency occur-
ence: fever (25.3%), hypoxia (20.4%), abnormality on
hest auscultation (19.9%), cough (12.9%), and tachy-
nea (12.9%). Seventy-four patients (94.9%) were re-
eiving antimicrobial medications, 59 patients (75.6%)
ere receiving antifungal medications, and 52 (66.7%)
ere receiving antiviral medications. Prior to BAL, 62
atients had a diffuse pulmonary process and 6 pa-
ients had focal disease identiﬁed by either chest ra-
iograph or CT. Ten patients had normal imaging
rior to the procedure. Twenty-six patients were in-
ubated prior to BAL (5 electively and 21 urgently).
even patients (9%) had a transbronchial biopsy per-
ormed at the time of BAL, and 16 patients (20.8%)
ad an open lung biopsy performed, 5 performed
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K. A. Kasow et al.834rior to the BAL. The physician on service deter-
ined the need for proceeding to an open lung bi-
psy, taking into consideration the patient’s clinical
tatus and any changes occurring since the BAL was
erformed. Upon analysis, none of these factors were
tatistically associated with the outcome of the BAL.
indings and Complications of BAL
Fifty-three patients (67.9%) had positive BAL
ndings, and more than 50% of these patients were
eceiving antimicrobial, antifungal, or antiviral agents,
ither for treatment or prophylaxis. The most com-
on ﬁnding was bacterial infection (46 patients). Of
he 53 patients who had a positive BAL, 30 (56.6%)
ad only 1 identiﬁed etiology (Table 2). Six patients
ad fungal infections identiﬁed by BAL, 2 were yeast,
were molds, and 1 was not able to be grown in
ulture but was present on Gram stain. Only 1
atient had a pre-BAL diagnosis of fungal pneumo-
ia; however, BAL results for this patient did not
dentify this type of infection. Thirty-nine alloge-
eic patients (50%) had 1 or more concurrent ex-
rapulmonary infections (viral alone: 14; fungal
lone: 10; bacterial alone: 7; fungal and viral: 5;
ungal and bacterial: 2; viral and bacterial: 1), and 30
76.9%) had a positive BAL. Ten patients had the
ame BAL ﬁnding as the concurrent infection; 4 had
ungal diseases, 4 had viral diseases, 1 had bacterial
nfection, and 1 had both viral and fungal infections.
wo patients had a pre-BAL diagnosis of aspergil-
osis; however, BAL was negative for fungal organ-
sms in both cases. One of these patients did not
ave any concurrent infections, whereas the other
ad aspergillosis in the brain and fungal retinitis.
ixty-ﬁve allogeneic recipients (83.3%) did not ex-
erience complications from the procedure. Ad-
erse events included hypoxia (7); respiratory dis-
able 2. Summary of BAL Findings of the 78 Allogeneic Recipients
nd the Number of Etiologies Discovered between the Pathological
eview and the Microbiological Evaluation
BAL Results Patients (n) %
Negative 25 32.1.%
Positive 53 67.9%
tiology (N  88 positive etiologies)
Bacterial infection 46 52.3%
Inflammation 15 17.0%
Viral infection 12 13.6%
Alveolar hemorrhage 8 9.1%
Fungal infection 6 6.8%
Unidentified organism 1 1.1%
umber of etiologies
One 30 56.6%
Two 15 28.3%
Three 5 9.4%
Four 2 3.8%
Five 1 1.9%sost patients had a positive ﬁnding and only one cause.ress, failure, or arrest (3); epistaxis (1);
aryngospasm (1); and epistaxis and laryngospasm
1). BAL results did not correspond with past pul-
onary complications.
Of the 7 patients who had a transbronchial biopsy
erformed at the time of BAL, all had positive BAL
ndings with 3 biopsy results correlating with the
AL results and 2 biopsy results proving the presence
f inﬂammation. The other 2 biopsy results differed
rom the BAL results, with 1 transbronchial biopsy
evealing the presence of viral inclusion bodies and
nother 1 revealing the presence of aspergillosis. Of
he 11 allogeneic patients who proceeded to an open
ung biopsy after BAL, 3 results correlated with the
AL results and 8 results did not correlate. Of the 8
pen lung biopsies performed within 30 days of BAL,
biopsy results correlated with the BAL results. Open
ung biopsy results were as follows: 8 inﬂammatory
hanges, 2 aspergillosis, 2 diffuse alveolar hemor-
hage, 1 viral infection (CMV), and 1 bacterial infec-
ion. Although our numbers are small for those pa-
ients undergoing transbronchial biopsies and/or open
ung biopsies, a transbronchial biopsy was only helpful
n 2 cases and would have changed management. In
ur patient population, an open lung biopsy did not
dentify a new infectious organism but rather con-
rmed the presence of inﬂammation, such as in bron-
hiolitis obliterans organizing pneumonia and inter-
titial ﬁbrosis.
Factors Related to BAL Diagnostic Yield. Sixty of the
8 allogeneic recipients (76.9%) were receiving im-
unosuppressive therapy at the time of BAL. Forty-
ine of these 78 patients (62.8%) had experienced
cute GVHD (20 grade 1, 13 grade 2, 7 grade 3), and
9 patients (24.3%) had cGVHD (limited in 15 pa-
ients). Grade II-IV aGVHD and the current use of
mmunosuppressive therapy had an impact on BAL
esults. Sixty percent of those with a negative BAL had
rade II-IV aGVHD whereas 26.4% of patients with
positive BAL had grade II-IV aGVHD; this was
tatistically signiﬁcant (P  .004). Furthermore, 96%
f those with negative BAL were receiving immuno-
uppressive therapy whereas 67.9% of those with pos-
tive BAL were receiving immunosuppressive therapy,
nd this was also statistically signiﬁcant (P  .008)
Table 3). Those without GVHD or with grade I
GVHD and/or not receiving immunosuppressive
herapy were more likely to have a positive BAL (Ta-
le 2). We performed an extensive analysis, including
isease classiﬁcation risk; prebronchoscopy intubation
nd whether urgent or elective; concurrent use of
ntibiotics, antifungals, antivirals, or immunosuppres-
ive medications; and history of pre-HSCT pulmo-
ary complications; however, we did not ﬁnd any
ther factors associated with BAL results or within the
ubset of patients with grade II-IV aGVHD (data not
hown).
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Bronchoalveolar Lavage in Pediatric HSCT 835Clinical Outcome. Of the 89 patients, 61 (68.5%)
ave died at the time of this report and 28 (31.4%)
emain alive. Primary causes of death included respi-
atory (29 patients), relapse disease or second malig-
ancy (8 patients), HSCT-related (8 patients), infec-
ious (3 patients), and other etiologies (13 patients).
ISCUSSION
Our study demonstrates that BAL can be safely
erformed in pediatric HSCT patients, and overall,
he potential beneﬁts of BAL outweigh its risks. The
rocedure is relatively rapid and may require minimal
edation, which is an important consideration in a
atient with respiratory distress. In contrast, an open
ung biopsy, another modality for determining the
tiology of respiratory complications, requires general
nesthesia and a postoperative chest tube. In a retro-
pective study of 19 patients at our institution who
nderwent open lung biopsy, the rate of postoperative
orbidity, which was likely attributable to the proce-
ure, was 47% at 30 days, and the 30-day survival rate
as 63.2%  10.6% [7] Sixteen patients in our study
able 3. Demographic and Clinical Data for 78 Allogeneic Patients Ac
Factors Overall
ge at BAL (in years)
Mean (standard deviation) 12.4 (6.1)
Median (range) 12.2 (0.8, 23.5)
ime between HSCT and BAL (in days)
Mean (standard deviation) 93.4 (93.7)
Median (range) 68 (6, 528)
re-BAL engraftment
No 12 (15.4)
Yes 66 (84.6)
cute GVHD
0 29 (37.2)
1 20 (25.6)
2 13 (16.7)
3 7 (9.0)
4 9 (11.5)
cute GVHD group
Grade 2-4 29 (37.2)
Grade 0-1 49 (62.8)
hronic GVHD
Extensive 4 (5.1)
N/A 59 (75.6)
Limited 15 (19.2)
mmunosuppressive therapy
No 18 (23.1)
Yes 60 (76.9)
AL indicates bronchoalveolar lavage; positive BAL, diagnostically
versus-host disease; HSCT, hematopoietic stem cell transplanta
he only factors that were statistically signiﬁcant between the BA
GVHD and/or the patient receiving immunosuppressive therap
complications, primary disease classiﬁcation, concurrent use o
intubation, electively or urgently prior to the BAL; none of
BAL-positive and -negative groups.nderwent open lung biopsy after BAL. Upon retro- cpective review of the BAL pathology report, 14 of
hese 16 patients had a positive BAL, suggesting that
n open lung biopsy is not necessarily required for
iagnostic purposes.
Although post-HSCT pulmonary complications
an have many causes, the diagnostic yield may be
imited in patients receiving immunosuppressive ther-
py or with grade II-IV GVHD. In our study, 53 of 78
llogeneic (67.9%) and 7 of 11 autologous (63.6%)
atients had a positive BAL, which may have altered
edical management. This rate is much higher than
hose previously reported (26%-51%) [8-12]. The fre-
uency of identiﬁcation of bacterial and fungal causes
as consistent with those previously reported [8,9].
leven of 60 patients (12.4%) with positive BAL ﬁnd-
ngs were diagnosed with diffuse alveolar hemorrhage,
lso consistent with previous reports [13,14]. Identiﬁ-
ation of an infectious or noninfectious cause leads to
ifferent therapeutic interventions. Whereas infec-
ious causes are predominantly treated with tailored
herapy (i.e., antibiotics for a bacterial infection), in-
ammation and diffuse alveolar hemorrhage may be
reated with a variety of therapies depending on the
to the Diagnostic Yield of BAL
By BAL
L Positive (n  53) BAL Negative (n  25) P-values
.68
12.2 (5.9) 12.8 (6.6)
11.9 (0.8, 23.5) 13.0 (2.6, 22.7)
.48
98.5 (96.7) 82.5 (87.9)
74 (7, 528) 58 (6, 361)
1.00
8 (15.1) 4 (16.0)
45 (84.9) 21 (84.0)
24 (45.3) 5 (20.0)
15 (28.3) 5 (20.0)
8 (15.1) 5 (20.0)
4 (7.5) 3 (12.0)
2 (3.8) 7 (28.0)
.004
14 (26.4) 15 (60.0)
39 (73.6) 10 (40.0)
.16
1 (1.9) 3 (12.0)
42 (79.2) 17 (68.0)
10 (18.9) 5 (20.0)
.008
17 (32.1) 1 (4.0)
36 (67.9) 24 (96.0)
ative; negative BAL, diagnostically uninformative; GVHD, graft-
A, not applicable.
tive and -negative groups were the presence of grade II-IV acute
r factors were analyzed, including history of pre-HSC pulmonary
iotics, antifungal, or antiviral agents, or if the patient required
variables revealed a signiﬁcant statistical difference between thecording
BA
inform
tion; N
L-posi
y. Othe
f antib
theselinical status [15].
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K. A. Kasow et al.836Although multiple patient characteristics, disease
haracteristics, and HSCT-related factors were ana-
yzed, only 2 differed signiﬁcantly between allogeneic
atients with positive (n  53) and negative (n  25)
AL results. Patients with grade II-IV aGVHD and
hose receiving immunosuppressive therapy were less
ikely than others to have an informative BAL, and
herefore, may be less likely to beneﬁt from BAL.
owever, we acknowledge that this ﬁnding may re-
ect the greater likelihood that patients in an immu-
ocompromised state were receiving antibiotic, anti-
iral, or antifungal agents at the time of BAL,
otentially at either prophylactic or therapeutic dos-
ge, and that the number of viable organisms and
nﬂammatory cells in the specimens may have been
educed for that reason. These patients may have
emained symptomatic leading to BAL for other rea-
ons, such as immunologically mediated pulmonary
isease, noninfectious etiologies such as diffuse alve-
lar hemorrhage, partially treated infections with re-
idual inﬂammatory cells, or a low colony number of
rug-resistant organisms, which were not found on
AL. Furthermore, patients with grade II-IV aGVHD
ere also more likely than others to be receiving
mmunosuppressive therapy. Moreover, BAL ﬂuid can
urrently only be tested for viral reactivation by poly-
erase chain reaction (PCR) for certain viruses, such
s CMV and HHV-6; unlike blood, where the possi-
ility of testing for a larger number of viruses is
reater. Hence, identifying a lower respiratory tract
iral infection may be more difﬁcult. As some patients
ay have noninfectious etiologies for the respiratory
ymptoms, other modalities for evaluation should be
onsidered, such as echocardiography, high-resolu-
ion CT, and pulmonary function tests, when feasible
o perform.
Bronchoalveolar lavage has limitations other than
hose identiﬁed in our study. Respiratory distress
aused by chemotherapy and radiation is difﬁcult to
iagnose by BAL. TBI and many of the chemothera-
eutic agents used in the preparative regimens, such as
usulfan, are known to cause respiratory complica-
ions after HSCT [16,17]. Further, in an emergent
ituation, a clinician is likely to begin empiric therapy
nd broaden prophylaxis coverage in the immuno-
ompromised patient before BAL is performed. The
rocedure requires a pulmonologist or an intensivist
nd may have to be scheduled, whereas a patient’s
ondition may indicate prompt broad coverage for
ultiple infectious agents. However, the yield of BAL
ay be low in some patients because of the experience
f the physician performing the BAL, the stability of
he patient during the procedure, and laboratory abil-
ty to identify organisms.
In conclusion, the safety and diagnostic yield of
AL appear to be relatively high in pediatric patients
ith respiratory distress after HSCT. Allogeneic re-ipients with grade II-IV aGVHD and those receiving
mmunosuppressive therapy are less likely than others
o beneﬁt from BAL. Other modalities, such as diag-
ostic imaging, may be an alternative for this cohort
f patients.
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